# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
RBC Capital analyst Brian Abrahams reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and maintains $181 price ...
These 10 stocks had the biggest drop last week, with McKesson Corporation, BIO-TECHNE Corp, and Warner Bros. Discovery, Inc. be...
RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and lowers the price targe...
Citigroup analyst David Hoang maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $...
Cantor Fitzgerald analyst Kristen Kluska maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price ta...